The key objectives include the assessment of the efficacy and safety of OQL011 and the identification of an optimal dosage for Phase III. Targeted oncology supportive therapy company OnQuality Pharmaceuticals has enrolled the first participant in Part 2 of the…
Lilly preps for rollout of its connected diabetes system
After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart…
Respiri recruits first patients in US wheezo programme
Australian digital health company Respiri has started to roll out its digital remote patient monitoring (RPM) system for asthma and chronic obstructive pulmonary disease (COPD) in the US, with the first patients now signed up to the programme. The Software…
Sanofi signs $1.2bn research alliance with AI specialist Insilico
Sanofi has tapped into the artificial intelligence expertise of Chinese biotech Insilico Medicine with a six-compound drug discovery collaboration that could be worth up to $1.2 billion. The alliance is backloaded, with $21.5 million paid upfront and Insilico also in…
People Receive Lab‑Grown Blood in World‑First Clinical Trial
In a first-of-its-kind clinical trial, blood grown in the laboratory has been transfused into people. If this technology is proven effective, lab-grown blood could potentially revolutionize treatment for people with blood disorders and rare blood types. Researchers say this trial…
Kintor concludes subject enrolment in Phase II acne vulgaris trial
The success rate of the treatment in each arm as per the five-point IGA scale by week 12 is the trial’s primary endpoint. Kintor Pharmaceutical has concluded subject enrolment in its Phase II clinical trial in China analysing KX-826 (pyrilutamide) to treat…
FDA grants IND clearance for Phase I trials of Phanes’ cancer antibody
PT217 has previously received orphan drug designation from the FDA to treat SCLC. The US Food and Drug Administration (FDA) has granted clearance for Phanes Therapeutics’ Investigational New Drug (IND) application to begin Phase I clinical trials of antibody PT217…
Alterity Therapeutics obtains approval in Australia to begin MSA therapy
The trial will assess the efficacy and safety of ATH434 in early-stage Multiple System Atrophy patients. Alterity Therapeutics has received the St. Vincent’s Hospital Melbourne Human Research Ethics Committee’s (HREC) approval to begin the Phase II clinical trial of ATH434…
ObvioHealth launches new patient engagement suite for clinical trials
The products and services are deployed through the ObvioGo platform and app and increase compliance and retention in clinical trials. Deployed through ObvioHealth’s ObvioGo platform and app, these products and services increase compliance and retention in clinical trials and deliver…
FDA grants funds for clinical trials in rare diseases
A contract will study if the physical evaluation of ALS patients in the at-home setting can reduce burden on patients. The US Food and Drug Administration (FDA) has awarded 19 new grants and two contracts worth over $38m to support…
